Compliance With Standard Therapies and Remission Rates After Implementation of an Infantile Spasms Management Guideline.

Abstract

BACKGROUND:

We implemented an infantile spasms management guideline recommending standard therapies and, early start of next treatment. After six years, we determined (1) our compliance with standard therapies, (2) time to next treatment, and (3) rate of initial and three-month electroclinical remission with first, second, and third treatments.

METHODS:

This is a retrospective record review of newly diagnosed spasms from September 2012 to September 2018, with the onset age of two months to two years.

RESULTS:

Standard therapies (hormone or vigabatrin) were the first treatments in 114 of 115 consecutive patients. The second and third treatments were started within 14 days of failed treatment in only 21% and 24%, respectively. Remission with the first and second treatments was similar (41% and 40%). Remission was lower for the third treatment (15%), although higher if standard therapy was used (36%). Initial and three-month remission by the first treatment was significantly higher for adrenocorticotropic hormone (ACTH, 66% and 79%, respectively) and prednisolone (53% and 83%, respectively) than for vigabatrin (19% and 40%, respectively). There were no significant differences in patient characteristics or rates of remission between ACTH and prednisolone.

CONCLUSIONS:

Although we achieved excellent compliance with standard therapies as initial treatment, a next treatment often started after two weeks. Given the superiority of hormone therapies over vigabatrin and standard therapies over nonstandard therapies, as well as the potentially negative impact of delays in effective treatment, future interventions need to focus on increasing the use of hormone over vigabatrin (for patients without tuberous sclerosis complex), use of standard therapies as second and third treatments, and reducing delays to next treatment.

• Authors: John R Mytinger, Dara V F Albert, Jaime D Twanow, Jorge Vidaurre, Yubo Tan, Guy N Brock, Adam P Ostendorf
• Journal: Pediatric neurology (Pediatr Neurol) Vol. 104 Pg. 23-29 (03 2020) ISSN: 1873-5150 [Electronic] United States
• PMID: 31911027 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• Anticonvulsants
• Glucocorticoids
• Adrenocorticotropic Hormone
• Prednisolone
• Vigabatrin

Topics

• Adrenocorticotropic Hormone (administration & dosage)
• Anticonvulsants (administration & dosage)
• Female
• Glucocorticoids (administration & dosage)
• Guideline Adherence
• Humans
• Infant
• Male
• Outcome and Process Assessment, Health Care
• Practice Guidelines as Topic
• Prednisolone (administration & dosage)
• Quality Assurance, Health Care
• Remission Induction
• Retrospective Studies
• Spasms, Infantile (drug therapy)
• Vigabatrin (administration & dosage)